Which has preferable valuation & earnings, GALT or ODTX?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Odyssey Therapeutics N/A N/A N/A -$6.77 N/A

Is GALT or ODTX more profitable?

Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Odyssey Therapeutics N/A N/A N/A

Does the media prefer GALT or ODTX?

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 1 articles in the media. Odyssey Therapeutics' average media sentiment score of 1.79 beat Galectin Therapeutics' score of 0.67 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Odyssey Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, GALT or SVRA?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is GALT or SVRA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Savara N/A -90.28% -68.95%

Does the media prefer GALT or SVRA?

In the previous week, Savara had 3 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Savara and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Savara's score of 0.45 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GALT or AKTS more profitable?

Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Aktis Oncology N/A N/A N/A

Does the media favor GALT or AKTS?

In the previous week, Aktis Oncology had 5 more articles in the media than Galectin Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Aktis Oncology's score of 0.15 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GALT or JANX more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Janux Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Janux Therapeutics N/A -11.89% -11.13%

Does the media prefer GALT or JANX?

In the previous week, Janux Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Janux Therapeutics and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Janux Therapeutics' score of 0.11 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation and earnings, GALT or ANL?

Galectin Therapeutics has higher earnings, but lower revenue than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Adlai Nortye $5M 194.36 -$35.53M N/A N/A

Is GALT or ANL more profitable?

Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Adlai Nortye N/A N/A N/A

Does the media refer more to GALT or ANL?

In the previous week, Adlai Nortye had 12 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Adlai Nortye and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Adlai Nortye's score of 0.19 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adlai Nortye 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Galectin Therapeutics (GALT) Competitors

$3.90 +0.14 (+3.72%)

As of 10/2/2026 04:00 PM Eastern

Compare

GALT vs. ODTX, SVRA, AKTS, JANX, and ANL

Should you buy Galectin Therapeutics stock or one of its competitors? Galectin Therapeutics's main competitors and comparable companies include Odyssey Therapeutics (ODTX), Savara (SVRA), Aktis Oncology (AKTS), Janux Therapeutics (JANX), and Adlai Nortye (ANL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Galectin Therapeutics compare to Odyssey Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 1 articles in the media. Odyssey Therapeutics' average media sentiment score of 1.79 beat Galectin Therapeutics' score of 0.67 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Odyssey Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Odyssey Therapeutics	N/A	N/A	N/A	-$6.77	N/A

Galectin Therapeutics presently has a consensus price target of $11.00, suggesting a potential upside of 182.05%. Odyssey Therapeutics has a consensus price target of $35.75, suggesting a potential upside of 72.46%. Given Galectin Therapeutics' higher possible upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Odyssey Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Odyssey Therapeutics	N/A	N/A	N/A

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Odyssey Therapeutics beats Galectin Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Galectin Therapeutics compare to Savara?

Galectin Therapeutics (NASDAQ:GALT) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 182.05%. Savara has a consensus price target of $10.00, suggesting a potential upside of 107.90%. Given Galectin Therapeutics' higher probable upside, equities research analysts clearly believe Galectin Therapeutics is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Savara had 3 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Savara and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Savara's score of 0.45 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Savara has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Galectin Therapeutics' return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Savara	N/A	-90.28%	-68.95%

Summary

Galectin Therapeutics and Savara tied by winning 7 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Aktis Oncology?

Galectin Therapeutics (NASDAQ:GALT) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Aktis Oncology had 5 more articles in the media than Galectin Therapeutics. MarketBeat recorded 6 mentions for Aktis Oncology and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Aktis Oncology's score of 0.15 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Galectin Therapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Aktis Oncology	$6.50M	153.15	-$63.73M	-$0.82	N/A

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Aktis Oncology	N/A	N/A	N/A

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 182.05%. Aktis Oncology has a consensus target price of $35.63, suggesting a potential upside of 92.36%. Given Galectin Therapeutics' higher possible upside, research analysts plainly believe Galectin Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Summary

Aktis Oncology beats Galectin Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to Janux Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Galectin Therapeutics' return on equity of 0.00% beat Janux Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Janux Therapeutics	N/A	-11.89%	-11.13%

Galectin Therapeutics has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market.

In the previous week, Janux Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Janux Therapeutics and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Janux Therapeutics' score of 0.11 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Galectin Therapeutics has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Janux Therapeutics	$10M	103.51	-$113.62M	-$1.64	N/A

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 182.05%. Janux Therapeutics has a consensus price target of $36.46, suggesting a potential upside of 115.37%. Given Galectin Therapeutics' higher possible upside, research analysts clearly believe Galectin Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Janux Therapeutics beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Adlai Nortye?

Galectin Therapeutics (NASDAQ:GALT) and Adlai Nortye (NASDAQ:ANL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Adlai Nortye	N/A	N/A	N/A

Galectin Therapeutics has higher earnings, but lower revenue than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Adlai Nortye	$5M	194.36	-$35.53M	N/A	N/A

Galectin Therapeutics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Adlai Nortye has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 182.05%. Adlai Nortye has a consensus target price of $29.50, suggesting a potential upside of 95.49%. Given Galectin Therapeutics' higher probable upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Adlai Nortye had 12 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Adlai Nortye and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Adlai Nortye's score of 0.19 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adlai Nortye	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Adlai Nortye beats Galectin Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$256.84M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.33%
P/E Ratio	-9.07	13.06	275.67	26.04
Price / Sales	N/A	1,292.17	656.66	110.58
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	-1.96	16.63	10.93	6.31
Net Income	-$30.84M	-$22.71M	$3.51B	$362.16M
7 Day Performance	N/A	-2.99%	-2.00%	-1.66%
1 Month Performance	-15.40%	-10.81%	-6.19%	-4.68%
1 Year Performance	-9.93%	19.19%	8.03%	1.57%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	1.804 of 5 stars	$3.90 +3.7%	$11.00 +182.1%	-9.9%	$256.84M	N/A	N/A	9
ODTX Odyssey Therapeutics	3.2027 of 5 stars	$21.67 +0.9%	$35.75 +65.0%	N/A	$1.04B	N/A	N/A	100
SVRA Savara	1.8033 of 5 stars	$5.03 -0.9%	$10.00 +99.0%	+37.8%	$1.03B	N/A	N/A	70	News Coverage Analyst Downgrade
AKTS Aktis Oncology	2.4913 of 5 stars	$19.18 -0.9%	$35.63 +85.7%	N/A	$1.03B	$6.50M	N/A	79	News Coverage Positive News Analyst Forecast
JANX Janux Therapeutics	2.3583 of 5 stars	$16.71 +0.8%	$36.46 +118.3%	-29.5%	$1.02B	$10M	N/A	113

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. ODTX, SVRA, AKTS, JANX, and ANL

How does Galectin Therapeutics compare to Odyssey Therapeutics?

Summary

How does Galectin Therapeutics compare to Savara?

Summary

How does Galectin Therapeutics compare to Aktis Oncology?

Summary

How does Galectin Therapeutics compare to Janux Therapeutics?

Summary

How does Galectin Therapeutics compare to Adlai Nortye?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. ODTX, SVRA, AKTS, JANX, and ANL

How does Galectin Therapeutics compare to Odyssey Therapeutics?

Does the media prefer GALT or ODTX?

Which has preferable valuation & earnings, GALT or ODTX?

Do analysts rate GALT or ODTX?

Is GALT or ODTX more profitable?

Do insiders & institutionals hold more shares of GALT or ODTX?

Summary

How does Galectin Therapeutics compare to Savara?

Do insiders and institutionals hold more shares of GALT or SVRA?

Which has preferable earnings & valuation, GALT or SVRA?

Do analysts recommend GALT or SVRA?

Does the media prefer GALT or SVRA?

Which has more volatility & risk, GALT or SVRA?

Is GALT or SVRA more profitable?

Summary

How does Galectin Therapeutics compare to Aktis Oncology?

Does the media favor GALT or AKTS?

Do insiders & institutionals hold more shares of GALT or AKTS?

Which has stronger valuation & earnings, GALT or AKTS?

Is GALT or AKTS more profitable?

Do analysts prefer GALT or AKTS?

Summary

How does Galectin Therapeutics compare to Janux Therapeutics?

Is GALT or JANX more profitable?

Which has more volatility and risk, GALT or JANX?

Does the media prefer GALT or JANX?

Which has better earnings and valuation, GALT or JANX?

Do analysts prefer GALT or JANX?

Do institutionals and insiders hold more shares of GALT or JANX?

Summary

How does Galectin Therapeutics compare to Adlai Nortye?

Is GALT or ANL more profitable?

Which has better valuation and earnings, GALT or ANL?

Which has more volatility & risk, GALT or ANL?

Do analysts prefer GALT or ANL?

Does the media refer more to GALT or ANL?

Do institutionals & insiders have more ownership in GALT or ANL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools